These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17268108)

  • 1. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors(1-6) VI. A series of new derivatives containing N,S- and N,SO2-spiro acetal scaffolds.
    Saitoh F; Nishida H; Mukaihira T; Kosuga N; Ohkouchi M; Matsusue T; Shiromizu I; Hosaka Y; Matsumoto M; Yamamoto I
    Chem Pharm Bull (Tokyo); 2007 Feb; 55(2):317-23. PubMed ID: 17268108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors V. A series of new derivatives containing a spiro[imidazo[1,2-a]pyrazine-2(3H),4'-piperidin]-5(1H)-one scaffold.
    Saitoh F; Mukaihira T; Nishida H; Satoh T; Okano A; Yumiya Y; Ohkouchi M; Johka R; Matsusue T; Shiromizu I; Hosaka Y; Matsumoto M; Ohnishi S
    Chem Pharm Bull (Tokyo); 2006 Nov; 54(11):1535-44. PubMed ID: 17077550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors IV. A series of new derivatives containing a spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one skeleton.
    Nishida H; Mukaihira T; Saitoh F; Harada K; Fukui M; Matsusue T; Okamoto A; Hosaka Y; Matsumoto M; Shiromizu I; Ohnishi S; Mochizuki H
    Chem Pharm Bull (Tokyo); 2004 Apr; 52(4):406-12. PubMed ID: 15056953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of acylguanidine FXa inhibitors.
    O'Connor SP; Atwal K; Li C; Liu EC; Seiler SM; Shi M; Shi Y; Stein PD; Wang Y
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4696-9. PubMed ID: 18644722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates.
    Hirayama F; Koshio H; Ishihara T; Watanuki S; Hachiya S; Kaizawa H; Kuramochi T; Katayama N; Kurihara H; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2002 Aug; 10(8):2597-610. PubMed ID: 12057649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spiro-substituted piperidines as neurokinin receptor antagonists. III. Synthesis of (+/-)-N-[2-(3,4-dichlorophenyl)-4-(spiro-substituted piperidin-1'-yl)butyl]-N-methylbenzamides and evaluation of NK1-NK2 dual antagonistic activities.
    Kubota H; Kakefuda A; Okamoto Y; Fujii M; Yamamoto O; Yamagiwa Y; Orita M; Ikeda K; Takeuchi M; Shibanuma T; Isomura Y
    Chem Pharm Bull (Tokyo); 1998 Oct; 46(10):1538-44. PubMed ID: 9810691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the terminal P4 domain in a series of D-phenylglycinamide-based factor Xa inhibitors.
    Franciskovich JB; Masters JJ; Weber WW; Klimkowski VJ; Chouinard M; Sipes PR; Johnson LM; Snyder DW; Chastain MK; Craft TJ; Towner RD; Gifford-Moore DS; Froelich LL; Smallwood JK; Foster RS; Smith GF; Liebeschuetz JW; Murray CW; Young SC
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6910-3. PubMed ID: 17976987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel and efficient direct synthesis of N,O-acetal compounds using a hypervalent iodine(III) reagent: an improved synthetic method for a key intermediate of discorhabdins.
    Harayama Y; Yoshida M; Kamimura D; Kita Y
    Chem Commun (Camb); 2005 Apr; (13):1764-6. PubMed ID: 15791325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological activity of novel factor Xa inhibitors: improving metabolic stability by S1 and S4 ligand modification.
    Komoriya S; Kobayashi S; Osanai K; Yoshino T; Nagata T; Haginoya N; Nakamoto Y; Mochizuki A; Nagahara T; Suzuki M; Shimada T; Watanabe K; Isobe Y; Furugoori T
    Bioorg Med Chem; 2006 Mar; 14(5):1309-30. PubMed ID: 16263291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copper-catalyzed [5+1] annulation of 2-ethynylanilines with an N,O-acetal leading to construction of quinoline derivatives.
    Sakai N; Tamura K; Shimamura K; Ikeda R; Konakahara T
    Org Lett; 2012 Feb; 14(3):836-9. PubMed ID: 22276849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of R-142086 as a factor Xa (FXa) inhibitor: syntheses and structure-activity relationships of cinnamyl derivatives.
    Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Niitsu Y; Asai F; Ishizuka T; Fujimoto K
    Chem Pharm Bull (Tokyo); 2009 Jan; 57(1):22-33. PubMed ID: 19122312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational synthesis of contra-thermodynamic spiroacetals by reductive cyclizations.
    Takaoka LR; Buckmelter AJ; LaCruz TE; Rychnovsky SD
    J Am Chem Soc; 2005 Jan; 127(2):528-9. PubMed ID: 15643869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structure-activity relationship of spiro[isochromanpiperidine] analogues for inhibition of histamine release.
    Yamato M; Hashigaki K; Ikeda M; Ohtake H; Tasaka K
    J Med Chem; 1981 Feb; 24(2):194-8. PubMed ID: 6162958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitor.
    Nishida H; Miyazaki Y; Kitamura Y; Ohashi M; Matsusue T; Okamoto A; Hosaka Y; Ohnishi S; Mochizuki H
    Chem Pharm Bull (Tokyo); 2001 Oct; 49(10):1237-44. PubMed ID: 11605647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor.
    Hirayama F; Koshio H; Katayama N; Kurihara H; Taniuchi Y; Sato K; Hisamichi N; Sakai-Moritani Y; Kawasaki T; Matsumoto Y; Yanagisawa I
    Bioorg Med Chem; 2002 May; 10(5):1509-23. PubMed ID: 11886813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitors.
    Kaptein A; Oubrie A; de Zwart E; Hoogenboom N; de Wit J; van de Kar B; van Hoek M; Vogel G; de Kimpe V; Schultz-Fademrecht C; Borsboom J; van Zeeland M; Versteegh J; Kazemier B; de Roos J; Wijnands F; Dulos J; Jaeger M; Leandro-Garcia P; Barf T
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3823-7. PubMed ID: 21565498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total Synthesis of Spiromamakone A and Structure Revision of Spiropreussione A.
    Tsukamoto H; Hanada S; Nomura Y; Doi T
    J Org Chem; 2018 Aug; 83(16):9430-9441. PubMed ID: 29895147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The first total synthesis of discorhabdin A.
    Tohma H; Harayama Y; Hashizume M; Iwata M; Kiyono Y; Egi M; Kita Y
    J Am Chem Soc; 2003 Sep; 125(37):11235-40. PubMed ID: 16220942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel SCD1 inhibitors: 5-alkyl-4,5-dihydro-3H-spiro[1,5-benzoxazepine-2,4'-piperidine] analogs.
    Uto Y; Ueno Y; Kiyotsuka Y; Miyazawa Y; Kurata H; Ogata T; Takagi T; Wakimoto S; Ohsumi J
    Eur J Med Chem; 2011 May; 46(5):1892-6. PubMed ID: 21356569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs.
    Young RJ; Campbell M; Borthwick AD; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Crowe MC; Dayal S; Diallo H; Kelly HA; King NP; Kleanthous S; Mason AM; Mordaunt JE; Patel C; Pateman AJ; Senger S; Shah GP; Smith PW; Watson NS; Weston HE; Zhou P
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5953-7. PubMed ID: 16982190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.